S&P 500   3,001.43 (-0.18%)
DOW   26,838.73 (+0.04%)
QQQ   192.30 (-0.56%)
AAPL   240.37 (-0.06%)
FB   183.20 (-3.46%)
MSFT   136.97 (-1.05%)
GOOGL   1,240.89 (-0.27%)
AMZN   1,764.78 (-1.17%)
CGC   20.94 (+2.90%)
NVDA   196.44 (+0.22%)
MU   44.80 (-0.93%)
BABA   169.53 (-2.30%)
GE   8.96 (+1.94%)
AMD   31.61 (-1.34%)
T   38.22 (-0.03%)
F   9.04 (+0.11%)
NFLX   266.85 (-4.03%)
BAC   31.15 (+0.42%)
GILD   66.06 (+1.30%)
DIS   132.75 (+1.91%)
S&P 500   3,001.43 (-0.18%)
DOW   26,838.73 (+0.04%)
QQQ   192.30 (-0.56%)
AAPL   240.37 (-0.06%)
FB   183.20 (-3.46%)
MSFT   136.97 (-1.05%)
GOOGL   1,240.89 (-0.27%)
AMZN   1,764.78 (-1.17%)
CGC   20.94 (+2.90%)
NVDA   196.44 (+0.22%)
MU   44.80 (-0.93%)
BABA   169.53 (-2.30%)
GE   8.96 (+1.94%)
AMD   31.61 (-1.34%)
T   38.22 (-0.03%)
F   9.04 (+0.11%)
NFLX   266.85 (-4.03%)
BAC   31.15 (+0.42%)
GILD   66.06 (+1.30%)
DIS   132.75 (+1.91%)
Log in

Medicure Stock Price, News & Analysis (CVE:MPH)

C$4.00
+0.10 (+2.56 %)
(As of 10/22/2019 03:13 PM ET)
Today's Range
C$3.81
Now: C$4.00
C$4.00
50-Day Range
C$3.81
MA: C$4.36
C$4.74
52-Week Range
C$3.75
Now: C$4.00
C$7.00
Volume766 shs
Average Volume7,745 shs
Market CapitalizationC$59.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medicure Inc., a cardiovascular pharmaceutical company, engages in the research, clinical development, and commercialization of human therapeutics in Canada, the United States, and Barbados. The company primarily markets and sells AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction, as well as AGGRASTAT high-dose bolus regimen for the reduction of thrombotic cardiovascular events in patients with non ST elevated acute coronary syndrome. The company's products also comprise PREXXARTAN, an oral solution used for the treatment of hypertension. In addition, it is developing TARDOXAL that is in Phase IIa clinical trials for the treatment of tardive dyskinesia/neurological indications; and products for the treatment of acute cardiology. Medicure Inc. was founded in 1997 and is headquartered in Winnipeg, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-204-4877412

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$26.43 million
Cash FlowC$3.04 per share
Book ValueC$5.01 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$59.48 million
Next Earnings Date11/19/2019 (Estimated)
OptionableNot Optionable

Receive MPH News and Ratings via Email

Sign-up to receive the latest news and ratings for MPH and its competitors with MarketBeat's FREE daily newsletter.


Medicure (CVE:MPH) Frequently Asked Questions

What is Medicure's stock symbol?

Medicure trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MPH."

How were Medicure's earnings last quarter?

Medicure Inc. (CVE:MPH) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.04. The business earned $6.30 million during the quarter, compared to analyst estimates of $5.60 million. View Medicure's Earnings History.

When is Medicure's next earnings date?

Medicure is scheduled to release their next quarterly earnings announcement on Tuesday, November 19th 2019. View Earnings Estimates for Medicure.

Has Medicure been receiving favorable news coverage?

Headlines about MPH stock have trended extremely negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medicure earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Medicure.

Who are some of Medicure's key competitors?

What other stocks do shareholders of Medicure own?

Who are Medicure's key executives?

Medicure's management team includes the folowing people:
  • Dr. Albert David Friesen, Founder, Chairman, CEO & Pres (Age 72)
  • Mr. James F. Kinley, CFO & Sec. (Age 41)

How do I buy shares of Medicure?

Shares of MPH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Medicure's stock price today?

One share of MPH stock can currently be purchased for approximately C$4.00.

How big of a company is Medicure?

Medicure has a market capitalization of C$59.48 million and generates C$26.43 million in revenue each year. View Additional Information About Medicure.

What is Medicure's official website?

The official website for Medicure is http://www.medicure.com/.

How can I contact Medicure?

Medicure's mailing address is 1250 Waverley St Suite 2, WINNIPEG, MB R3T 6C6, Canada. The company can be reached via phone at +1-204-4877412.


MarketBeat Community Rating for Medicure (CVE MPH)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about Medicure and other stocks. Vote "Outperform" if you believe MPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel